LEADER 05606nam 2200757Ia 450 001 9910825792303321 005 20200520144314.0 010 $a1-282-36851-6 010 $a9786612368516 010 $a0-470-47328-2 010 $a0-470-47327-4 035 $a(CKB)1000000000821994 035 $a(EBL)468819 035 $a(OCoLC)609847549 035 $a(SSID)ssj0000290886 035 $a(PQKBManifestationID)11232773 035 $a(PQKBTitleCode)TC0000290886 035 $a(PQKBWorkID)10229957 035 $a(PQKB)10639855 035 $a(MiAaPQ)EBC468819 035 $a(Au-PeEL)EBL468819 035 $a(CaPaEBR)ebr10346015 035 $a(CaONFJC)MIL236851 035 $a(PPN)191675628 035 $a(OCoLC)319126638 035 $a(FINmELB)ELB178385 035 $a(EXLCZ)991000000000821994 100 $a20090420d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCarbohydrate-based vaccines and immunotherapies /$fedited by Zhongwu Guo, Geert-Jan Boons 205 $a1st ed. 210 $aHoboken, N.J. ;$aOxford, [UK] $cWiley$dc2009 215 $a1 online resource (436 p.) 225 1 $aWiley series in drug discovery and development 300 $aDescription based upon print version of record. 311 $a0-470-19756-0 320 $aIncludes bibliographical references and index. 327 $aCARBOHYDRATE-BASED VACCINES AND IMMUNOTHERAPIES; CONTENTS; Preface; Contributors; 1 Glycobiology and Immunology; 1.1 Introduction; 1.2 Glycobiology; 1.2.1 Glycosylation-Is It Worth the Cost?; 1.2.2 Glycan Biosynthesis-A Dauntingly Complex Process; 1.2.3 Glycoproteins; 1.2.4 Lipid-Based Glycans; 1.2.5 Polysaccharides: Glycosaminoglycans and Bacterial Capsular Components; 1.3 The Immune System; 1.3.1 Introductory Comments; 1.3.2 Overview of the Immune System; 1.3.3 Glycoimmunobiology; 1.3.4 Interplay between Glycosylation and Sugars: a Two-Way Street; 1.4 Carbohydrate Antigens 327 $a1.4.1 Carbohydrate Antigens in Humans1.4.2 Carbohydrates and Pathogens; 1.4.3 Carbohydrate-Based Vaccines; 1.4.4 Concluding Comments: Building on Success; Acknowledgment; References; 2 Preparation of Glycoconjugate Vaccines; 2.1 Introduction; 2.2 Capsular Polysaccharide-Protein Conjugates; 2.2.1 Haemophilus influenzae Type b; 2.2.2 Streptococcus pneumoniae; 2.2.3 Neisseria meningitidis; 2.2.4 Salmonella typhi Vi; 2.2.5 Group B Streptococcus; 2.2.6 Staphylococcus aureus Types 5 and 8; 2.3 Lipopolysaccharide (LPS) and Lipooligosaccharide (LOS) Conjugates; 2.3.1 Escherichia coli O157 327 $a2.3.2 Vibrio cholerae O1 and O1392.3.3 Shigella dysenteriae Type 1, sonnei and flexneri 2a; 2.3.4 Neisseria meningitidis and Nontypeable Haemophilus influenzae; 2.4 Total Synthetic Glycoconjugate Vaccines; References; 3 Adjuvants for Protein- and Carbohydrate-Based Vaccines; 3.1 Introduction; 3.2 Initiation and Stimulation of Adaptive Responses; 3.3 "Old" Adjuvants and Formulations; 3.3.1 Aluminum; 3.3.2 Emulsions; 3.3.3 Saponins, QS21, and ISCOMS; 3.3.4 Liposomes and Microparticles; 3.3.5 Antigen/Formulation Targeting; 3.3.6 Induction of CD8 CTLs with Soluble Antigens 327 $a3.4 Renaissance of Innate Immunity3.4.1 Toll-Like Receptors: Agonists and Roles; 3.4.2 Non-TLRs Innate Receptors; 3.4.3 Other Receptors Involved in Antigen Capture and Recognition; 3.5 From Basic Research to Practical Applications: Identification of New Adjuvants; 3.5.1 TLR Synthetic Agonists; 3.5.2 Combination of PRR Agonists; 3.6 Adjuvants for Carbohydrate-Based Vaccines; 3.6.1 Td and Ti B-Cell Responses; 3.6.2 Adjuvants for "Free" Polysaccharides (Ti Antigens); 3.6.3 Adjuvants for Glycoconjugate Vaccines (T-Dependent Antigens) 327 $a3.7 Combinations of Adjuvants: Preclinical and Clinical Developments3.8 Immunomodulation of Existing Responses: Adjuvants for Therapeutic Vaccines; 3.9 Take Another Route; 3.9.1 Adjuvants for Mucosal Immunization; 3.9.2 Epidermal or Intradermal Routes; 3.10 Practical Aspects of Adjuvant Development; 3.10.1 Regulatory Aspects; 3.10.2 Safety versus Efficacy: Risk-Benefit Ratio; 3.11 Preclinical Models Used in Adjuvant Development; 3.11.1 Animal Models; 3.11.2 In vitro Models; 3.12 Conclusions and Perspectives; Acknowledgment; References; 4 Carbohydrate-Based Antibacterial Vaccines 327 $a4.1 Introduction 330 $aThe fundamental science and the latest developments in carbohydrate-based vaccines The relatively new field of glycoimmunology has emerged from the marriage of glycobiology and immunology, in recognition of the important role carbohydrates play as antigenic determinants. Carbohydrate-Based Vaccines and Immunotherapies comprehensively reviews the state of this exciting field, offering a single source for both the fundamental science and the latest developments. With contributions by leading experts, this resource covers the design, synthesis, evaluation, and applications of va 410 0$aWiley series in drug discovery and development. 606 $aCarbohydrates$xImmunology 606 $aVaccines 606 $aGlycoconjugates$xImmunology 615 0$aCarbohydrates$xImmunology. 615 0$aVaccines. 615 0$aGlycoconjugates$xImmunology. 676 $a616.07/9 676 $a616.079 701 $aGuo$b Zhongwu$01655284 701 $aBoons$b Geert-Jan$0877768 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910825792303321 996 $aCarbohydrate-based vaccines and immunotherapies$94007607 997 $aUNINA